Successful lymphoablative autologous haematopoietic stem cell transplantation in three cases of severe autoimmune disease despite reduced dose cyclophosphamide conditioning-do we need 200 mg/kg cyclophosphamide?

Ross Penglase^{1

2

3}, Helen Englert⁴, Kathleen Tymms^{5

6}, Andrew Carr⁷, David Ma^{8

9

4}, Sam Milliken⁴, John Moore^{8

9

4}

Affiliations

¹ Rheumatology Department, St Vincent's Hospital, Sydney, NSW, Australia. ross.penglase@svha.org.au.
² St Vincent's Centre for Applied Medical Research, Sydney, NSW, Australia. ross.penglase@svha.org.au.
³ University of New South Wales, Medical School, Sydney, NSW, Australia. ross.penglase@svha.org.au.
⁴ Haematology Department, St Vincent's Hospital, Sydney, NSW, Australia.
⁵ Canberra Rheumatology, Canberra, ACT, Australia.
⁶ Rheumatology Department, Canberra Hospital, Canberra, ACT, Australia.
⁷ Immunology Department, St Vincent's Hospital, Sydney, NSW, Australia.
⁸ St Vincent's Centre for Applied Medical Research, Sydney, NSW, Australia.
⁹ University of New South Wales, Medical School, Sydney, NSW, Australia.

Ross Penglase et al. Bone Marrow Transplant. 2022 Jul.

. 2022 Jul;57(7):1207-1209.

doi: 10.1038/s41409-022-01696-5. Epub 2022 May 6.

Ross Penglase^{1

2

3}, Helen Englert⁴, Kathleen Tymms^{5

6}, Andrew Carr⁷, David Ma^{8

9

4}, Sam Milliken⁴, John Moore^{8

9

4}

¹ Rheumatology Department, St Vincent's Hospital, Sydney, NSW, Australia. ross.penglase@svha.org.au.
² St Vincent's Centre for Applied Medical Research, Sydney, NSW, Australia. ross.penglase@svha.org.au.
³ University of New South Wales, Medical School, Sydney, NSW, Australia. ross.penglase@svha.org.au.
⁴ Haematology Department, St Vincent's Hospital, Sydney, NSW, Australia.
⁵ Canberra Rheumatology, Canberra, ACT, Australia.
⁶ Rheumatology Department, Canberra Hospital, Canberra, ACT, Australia.
⁷ Immunology Department, St Vincent's Hospital, Sydney, NSW, Australia.
⁸ St Vincent's Centre for Applied Medical Research, Sydney, NSW, Australia.
⁹ University of New South Wales, Medical School, Sydney, NSW, Australia.

No abstract available

References

1. Burt RK, Shah SJ, Dill K, Grant T, Gheorghiade M, Schroeder J, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 2011;378:498–506. - DOI
1. Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, et al. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. N Engl J Med. 2018;378:35–47. - DOI
1. Sullivan KM, Majhail NS, Bredeson C, Carpenter PA, Chatterjee S, Crofford LJ, et al. Systemic Sclerosis as an Indication for Autologous Hematopoietic Cell Transplantation: Position Statement from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Tr. 2018;24:1961–4. - DOI
1. van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014;311:2490–8. - DOI
1. Spierings J, van Rhenen A, Welsing PM, Marijnissen AC, De Langhe E, Del, Papa N, et al. A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol. BMJ Open. 2021;11:e044483. - DOI